Oncotelic Therapeutics, Inc. (OTCQB: OTLC) announced that its proprietary PDAOAI drug discovery and development platform will be featured during the Product & Engineering keynote at Qdrant Vector Space Day 2026 in San Francisco on June 11. Company executives will join Qdrant leadership to discuss how PDAOAI, operating on Qdrant infrastructure, has helped accelerate the development of two drug candidates from concept to investigational new drug (IND) filings in less than two years, significantly reducing the time and cost traditionally associated with pharmaceutical development.
The presentation will highlight several innovations underpinning the platform, including a proprietary "manifold folding" technique designed to improve semantic retrieval accuracy and reduce large language model hallucinations, as well as the indexing of approximately 28 million PubMed biomedical abstracts on Qdrant Cloud. Oncotelic said the platform leverages advanced vector search technologies to support large-scale biomedical research and accelerate oncology drug discovery efforts. The company's ability to compress the typical drug development timeline from years to under two years for two candidates underscores the platform's potential to reshape the industry's cost and efficiency benchmarks.
Oncotelic Therapeutics is a clinical-stage biopharmaceutical company focused on oncology and immunotherapy products targeting high-unmet-need cancers and rare pediatric indications. Beyond its directly owned pipeline, the company benefits from over 500 patent applications and 75 issued patents held by its CEO, Dr. Vuong Trieu. The PDAOAI platform supports research, biomarker discovery, and regulatory processes through advanced data analysis and knowledge integration. Oncotelic also licenses and co-develops select drug candidates through strategic partnerships, including a 45% interest in GMP Bio, a joint venture advancing a complementary pipeline of therapeutic candidates.
The Qdrant Vector Space Day event provides a venue for Oncotelic to demonstrate how its AI-driven approach can address longstanding bottlenecks in drug discovery. By indexing 28 million PubMed abstracts and employing manifold folding to enhance retrieval accuracy, PDAOAI aims to reduce the risk of AI hallucinations that can mislead researchers. This technical advancement could have broad implications for the pharmaceutical industry, where the average cost to bring a new drug to market exceeds $1 billion and often takes a decade or more.
For more information about Oncotelic, visit the company's newsroom at https://ibn.fm/OTLC. The full press release is available at https://ibn.fm/Ce72F.
